![[fetch_key]](https://stocktradeupdates.com/wp-content/uploads/new_logos/DIVISLAB.png)
Share the post "Divi’s Laboratories ‘s Q3 2024-25 Latest News: Revenue Grows by 25.01% YoY"
Highlights
🔹 The presented financial data is Consolidated to provide a comprehensive overview of the company performance. 🔹 Sales over the Year and quarter: The company experienced a substantial growth of 25.01 % in the past year, decrease in net sales/revenue by -0.81 %. 🔹 Income over the Year and quarter: There has been decline in other income over the past year which is -13.68 %, Marginal decrease of -22.64% in other income during this quarter. 🔹 Profit over the Year and quarter: Significant improvement in profitability for Divi’s Laboratories Limited. Notable increase of 64.53 % in net profit Year to Year, Divi’s Laboratories Limited’s profitability increased by 15.49 % in this quarter. 🔹 EPS over the Year and quarter: EPS increased by 64.44 % Year to Year. EPS increased by 15.63 % in previous quarter. Positive impact on shareholders.
| Metrics | Previous Year | Previous Quarter | Current Quarter | Quarter to Quarter Difference | Year to Year Difference |
|---|---|---|---|---|---|
| Sales | Rs. 1855 Cr | Rs. 2338 Cr | Rs. 2319 Cr | -0.81 % | + 25.01 % |
| Expenses | Rs. 1366 Cr | Rs. 1622 Cr | Rs. 1576 Cr | -2.84 % | + 15.37 % |
| Operating Profit | Rs. 489 Cr | Rs. 716 Cr | Rs. 743 Cr | + 3.77 % | + 51.94 % |
| OPM % | 26.36 % | 30.62 % | 32.04 % | + 1.42 % | + 5.68 % |
| Other Income | Rs. 95 Cr | Rs. 106 Cr | Rs. 82 Cr | -22.64 % | -13.68 % |
| Interest | Rs. 0 Cr | Rs. 1 Cr | Rs. 0 Cr | 0 % | 0 % |
| Depreciation | Rs. 95 Cr | Rs. 99 Cr | Rs. 99 Cr | + 0 % | + 4.21 % |
| Profit before tax | Rs. 489 Cr | Rs. 722 Cr | Rs. 726 Cr | + 0.55 % | + 48.47 % |
| Tax % | 26.79 % | 29.36 % | 18.87 % | -10.49 % | -7.92 % |
| Net Profit | Rs. 358 Cr | Rs. 510 Cr | Rs. 589 Cr | + 15.49 % | + 64.53 % |
| EPS in Rs | Rs. 13.5 | Rs. 19.2 | Rs. 22.2 | + 15.63 % | + 64.44 % |
Today, we’re looking at Divi’s Laboratories Limited’s financial performance for the Q3(Dec 2024-25).Starting with the top line, the company reported a robust year-over-year sales growth of 25.01 %. However, it did see a marginal slip of -0.81 % from the previous quarter. Expenses decreased slightly by -2.84 % quarter-on-quarter, aligning with the annual rise of 15.37 %. Operating profit, while up 51.94 % compared to last year, faced a quarter-on-quarter increase of 3.77 %, signaling a short-term expansion in margins.
The Operating Profit Margin (OPM) % echoes this narrative, showing resilience on an annual basis with an increase of 5.68 %, but an expansion of 1.42 % sequentially. Other income fell by -22.64 % compared to the last quarter, despite an annual decline of -13.68 %. Depreciation costs climbed by 0 % quarter-on-quarter, whereas on an annual scale, they saw an increase of 4.21 %. Profit before tax grew annually by 48.47 % but saw an increase from the preceding quarter by 0.55 %.
Tax expenses as a percentage of profits decreased slightly by -7.92 % compared to last year, with a more notable quarter-on-quarter decrease of -10.49 %. Net profit rose by 64.53 % year-on-year but experienced a 15.49 % expansion from the last quarter. And finally, Earnings Per Share (EPS) displayed an annual uptick of 64.44 % but a quarterly rise of 15.63 %. In summary, Divi’s Laboratories Limited’s annual performance indicates steady growth, although the quarter-on-quarter figures suggest some areas may require strategic attention.
| Metrics | Previous Year | Previous Quarter | Current Quarter | Quarter to Quarter Difference | Year to Year Difference |
|---|---|---|---|---|---|
| Sales | Rs. 1855 Cr | Rs. 2338 Cr | Rs. 2319 Cr | -0.81 % | + 25.01 % |
| Expenses | Rs. 1366 Cr | Rs. 1622 Cr | Rs. 1576 Cr | -2.84 % | + 15.37 % |
| Operating Profit | Rs. 489 Cr | Rs. 716 Cr | Rs. 743 Cr | + 3.77 % | + 51.94 % |
| Net Profit | Rs. 358 Cr | Rs. 510 Cr | Rs. 589 Cr | + 15.49 % | + 64.53 % |
| EPS in Rs | Rs. 13.5 | Rs. 19.2 | Rs. 22.2 | + 15.63 % | + 64.44 % |
In reviewing Divi’s Laboratories Limited’s 2024-25(Q3) financial snapshot, key trends emerge, shedding light on the company’s performance.Sales saw a robust 25.01 % year-on-year growth, although there was a slight dip of -0.81 % from the previous quarter. Expenses rose by 15.37 % compared to the previous year, with a decrease of -2.84 % quarter-on-quarter. Operating Profit surged by 51.94 % annually, and saw a 3.77 % increase from the last quarter.
Net Profit showed yearly increase of 64.53 %, and experienced a 15.49 % increase from the previous quarter. Earnings Per Share (EPS) rose by 64.44 % annually, however rose by 15.63 % compared to the last quarter. In essence, while Divi’s Laboratories Limited exhibits strong annual growth indicators, short-term improvements suggest the potential for recovery and the importance of strategic adjustments to counter market challenges effectively. That’s all for now in the financial sector.
